{
    "nct_id": "NCT03825510",
    "official_title": "A Prospective Trail of Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for the Treatment of Metastatic Lung Cancer: SBRT Sensitization of the Programmed Death-1 (PD-1) Effect",
    "inclusion_criteria": "* Histologically or cytologically confirmed Stage IV NSCLC according to the 7th AJCC staging manual.\n* Eligible for an immunotherapy agent. Patients who progress after drug therapy (3 months) for ALK, EGFR or ROS mutation positive lung cancer are eligible.\n* At least 2 lesions that are safely amenable to SBRT. ECOG <=2.\n* At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessment or at least 1 lesion with FDG avidity and CT correlate that can be monitored for PET-CT response by SUV Max increase or decrease.\n* Normal Hepatic and renal function.\n* Bone marrow reserve:\n\n  1. ANC ≥ 1.5 x 109/L\n  2. Hemoglobin ≥9.0 g/dL\n  3. Platelet count ≥75 x 109/L\n* Ability to comply with follow-up visits and evaluations, treatment planning and studies and other study related procedures and visits.\n* Ability to sign informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with active CNS metastases\n* Active, known or suspected auto-immune disease.\n* Patients with medical conditions that require systemic immunosuppression.\n* Patients with a history of interstitial lung disease.\n* Prior treatment with immune checkpoint inhibitors/immonotherapy.\n* Other active malignancy requiring intervention.\n* Prior lung radiation, with the only metastatic targets in the lungs.\n* Unresolved toxicity from prior chemotherapy or anti-cancer treatment.\n* Current or prior enrollment in clinical trial with an investigational drug within 4 weeks.\n* Pregnancy or positive pregnancy test.",
    "miscellaneous_criteria": ""
}